Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2024 07:58 ET | Source: Foghorn Therapeutics, Inc.

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common...
May 06, 2024 07:00 ET | Source: Foghorn Therapeutics, Inc.

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation...
April 16, 2024 07:00 ET | Source: Foghorn Therapeutics, Inc.

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
April 09, 2024 16:30 ET | Source: Foghorn Therapeutics, Inc.

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically; IND filing on track for Q2...
April 05, 2024 07:00 ET | Source: Foghorn Therapeutics, Inc.

Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
March 26, 2024 07:00 ET | Source: Foghorn Therapeutics, Inc.

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader...
March 07, 2024 07:00 ET | Source: Foghorn Therapeutics, Inc.

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 • FHD-909, a first-in-class BRM selective inhibitor, selected for...
March 05, 2024 16:48 ET | Source: Foghorn Therapeutics, Inc.

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024Oral...
February 28, 2024 07:00 ET | Source: Foghorn Therapeutics, Inc.

Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
February 08, 2024 07:00 ET | Source: Foghorn Therapeutics, Inc.

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...